Inflammation as a causative factor in the aetiology of Parkinson's disease
暂无分享,去创建一个
[1] N. Rothwell,et al. The role of inflammation in CNS injury and disease , 2006, British journal of pharmacology.
[2] P. Riederer,et al. Brain beta 2-microglobulin levels are elevated in the striatum in Parkinson's disease. , 1995, Journal of neural transmission. Parkinson's disease and dementia section.
[3] J. Schulz,et al. Inhibition of Neuronal Nitric Oxide Synthase by 7‐Nitroindazole Protects Against MPTP‐Induced Neurotoxicity in Mice , 1995, Journal of neurochemistry.
[4] C. Ferrari,et al. Microglial activation with atypical proinflammatory cytokine expression in a rat model of Parkinson's disease , 2003, The European journal of neuroscience.
[5] Hideki Hayakawa,et al. Caspase-11 Mediates Inflammatory Dopaminergic Cell Death in the 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine Mouse Model of Parkinson's Disease , 2004, The Journal of Neuroscience.
[6] B. Liu,et al. Novel anti-inflammatory therapy for Parkinson's disease. , 2003, Trends in pharmacological sciences.
[7] Belinda Wilson,et al. Aggregated α‐synuclein activates microglia: a process leading to disease progression in Parkinson's disease , 2005, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[8] K. Vrana,et al. Cytotoxic and genotoxic potential of dopamine , 1999, Journal of neuroscience research.
[9] E. Masliah,et al. Increased level of DJ-1 in the cerebrospinal fluids of sporadic Parkinson's disease. , 2006, Biochemical and biophysical research communications.
[10] Bin Liu,et al. NADPH Oxidase Mediates Lipopolysaccharide-induced Neurotoxicity and Proinflammatory Gene Expression in Activated Microglia* , 2004, Journal of Biological Chemistry.
[11] Bin Liu,et al. Microglial activation‐mediated delayed and progressive degeneration of rat nigral dopaminergic neurons: relevance to Parkinson's disease , 2002, Journal of neurochemistry.
[12] S. Paul,et al. Minocycline prevents nigrostriatal dopaminergic neurodegeneration in the MPTP model of Parkinson's disease , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[13] J. Ghika. [Genetics of parkinsonism]. , 2000, Revue medicale de la Suisse romande.
[14] H. Ahsan,et al. Oxygen free radicals and systemic autoimmunity , 2003, Clinical and experimental immunology.
[15] R. Rodnitzky,et al. Histological and biochemical pathology in a family with autosomal dominant Parkinsonism and dementia , 1993 .
[16] Andis Klegeris,et al. Alpha‐synuclein and its disease‐causing mutants induce ICAM‐1 and IL‐6 in human astrocytes and astrocytoma cells , 2006, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[17] S. Minoshima,et al. Familial Parkinson's disease. Alpha-synuclein and parkin. , 2001, Advances in neurology.
[18] G. Raivich,et al. Systemic LPS Injection Leads to Granulocyte Influx into Normal and Injured Brain: Effects of ICAM-1 Deficiency , 2001, Experimental Neurology.
[19] T. Sherer,et al. Environment, Mitochondria, and Parkinson's Disease , 2002, The Neuroscientist : a review journal bringing neurobiology, neurology and psychiatry.
[20] G. Wilkin,et al. Inflammatory Regulators in Parkinson's Disease: iNOS, Lipocortin-1, and Cyclooxygenases-1 and -2 , 2000, Molecular and Cellular Neuroscience.
[21] P. Riederer,et al. Interleukin-1β, interleukin-6, epidermal growth factor and transforming growth factor-α are elevated in the brain from parkinsonian patients , 1994, Neuroscience Letters.
[22] D. Graham,et al. Autoxidation versus covalent binding of quinones as the mechanism of toxicity of dopamine, 6-hydroxydopamine, and related compounds toward C1300 neuroblastoma cells in vitro. , 1978, Molecular pharmacology.
[23] P. Mander,et al. Involvement of inducible nitric oxide synthase in inflammation-induced dopaminergic neurodegeneration , 2002, Neuroscience.
[24] S. Kish,et al. In situ detection of apoptotic nuclei in the substantia nigra compacta of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated mice using terminal deoxynucleotidyl transferase labelling and acridine orange staining , 1997, Neuroscience.
[25] T. Nagatsu,et al. Parkinson's disease: changes in apoptosis-related factors suggesting possible gene therapy , 2002, Journal of Neural Transmission.
[26] B. Ferger,et al. Inhibition of the cyclooxygenase isoenzymes COX‐1 and COX‐2 provide neuroprotection in the MPTP‐mouse model of Parkinson's disease , 2001, Synapse.
[27] M. Hengartner. The biochemistry of apoptosis , 2000, Nature.
[28] B. Liu,et al. Role of Nitric Oxide in Inflammation‐Mediated Neurodegeneration , 2002, Annals of the New York Academy of Sciences.
[29] M. Sawada,et al. Cellular and Molecular Mechanisms of Parkinson’s Disease: Neurotoxins, Causative Genes, and Inflammatory Cytokines , 2006, Cellular and Molecular Neurobiology.
[30] B. Liu,et al. Distinct Role for Microglia in Rotenone-Induced Degeneration of Dopaminergic Neurons , 2002, The Journal of Neuroscience.
[31] K. Barron. The microglial cell. A historical review , 1995, Journal of the Neurological Sciences.
[32] J. Antel,et al. Glial cell influence on the human blood‐brain barrier , 2001, Glia.
[33] J. Bart,et al. Blood–brain barrier dysfunction in parkinsonian midbrain in vivo , 2005, Annals of neurology.
[34] T. L. Collins,et al. Adhesion receptors in lymphocyte activation. , 1994, Current opinion in immunology.
[35] J. Cano,et al. Dopamine‐dependent neurotoxicity of lipopolysaccharide in substantia nigra , 2005, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[36] L. Adorini,et al. Regulation of T-cell responses by CNS antigen-presenting cells: different roles for microglia and astrocytes. , 2000, Immunology today.
[37] Dong-Kug Choi,et al. Cyclooxygenase-2 is instrumental in Parkinson's disease neurodegeneration , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[38] A. Lang,et al. Parkinson's disease. First of two parts. , 1998, The New England journal of medicine.
[39] J. Schneider-Mergener,et al. FAN, a Novel WD-Repeat Protein, Couples the p55 TNF-Receptor to Neutral Sphingomyelinase , 1996, Cell.
[40] J. Miklossy,et al. Role of ICAM-1 in persisting inflammation in Parkinson disease and MPTP monkeys , 2006, Experimental Neurology.
[41] H. Ichinose,et al. Cytokines in Parkinson's disease. , 2000, Journal of neural transmission. Supplementum.
[42] A. Schapira,et al. Mitochondrial involvement in Parkinson's disease, Huntington's disease, hereditary spastic paraplegia and Friedreich's ataxia. , 1999, Biochimica et biophysica acta.
[43] G. Bing,et al. Interleukin-10 protects against inflammation-mediated degeneration of dopaminergic neurons in substantia nigra , 2007, Neurobiology of Aging.
[44] E. Hirsch,et al. Immunocytochemical analysis of tumor necrosis factor and its receptors in Parkinson's disease , 1994, Neuroscience Letters.
[45] H. Vanderstichele,et al. An in vitro model for the study of microglia-induced neurodegeneration: involvement of nitric oxide and tumor necrosis factor-α , 2001, Neurochemistry International.
[46] B. Liu,et al. Dextromethorphan Protects Dopaminergic Neurons against Inflammation-Mediated Degeneration through Inhibition of Microglial Activation , 2003, Journal of Pharmacology and Experimental Therapeutics.
[47] Zh Feng,et al. Cyclooxygenase-2-deficient mice are resistant to 1-methyl-4-phenyl1, 2, 3, 6-tetrahydropyridine-induced damage of dopaminergic neurons in the substantia nigra , 2002, Neuroscience Letters.
[48] P. Carvey,et al. Lipopolysaccharide (LPS)-induced dopamine cell loss in culture: roles of tumor necrosis factor-α, interleukin-1β, and nitric oxide , 2002 .
[49] M. Miura,et al. Neurotoxic Effects of Lipopolysaccharide on Nigral Dopaminergic Neurons Are Mediated by Microglial Activation, Interleukin-1β, and Expression of Caspase-11 in Mice* , 2004, Journal of Biological Chemistry.
[50] H. Ichinose,et al. Increase in level of tumor necrosis factor (TNF)-α in 6-hydroxydopamine-lesioned striatum in rats without influence of systemic l-DOPA on the TNF-α induction , 1999, Neuroscience Letters.
[51] S. Tufik,et al. Different parkinsonism models produce a time-dependent induction of COX-2 in the substantia nigra of rats , 2006, Brain Research.
[52] M. Hoehn,et al. Parkinsonism , 1998, Neurology.
[53] K. Suk,et al. Hypoxic induction of caspase-11/caspase-1/interleukin-1beta in brain microglia. , 2003, Brain research. Molecular brain research.
[54] M. Beal. Mitochondria, Oxidative Damage, and Inflammation in Parkinson's Disease , 2003, Annals of the New York Academy of Sciences.
[55] Georg W. Kreutzberg,et al. Neuroglial activation repertoire in the injured brain: graded response, molecular mechanisms and cues to physiological function , 1999, Brain Research Reviews.
[56] Beata Sikorska,et al. Microglial cells in neurodegenerative disorders. , 2006, Folia neuropathologica.
[57] B. Liu,et al. Synergistic Dopaminergic Neurotoxicity of the Pesticide Rotenone and Inflammogen Lipopolysaccharide: Relevance to the Etiology of Parkinson's Disease , 2003, The Journal of Neuroscience.
[58] P Riederer,et al. Interleukin-1 beta and interleukin-6 are elevated in the cerebrospinal fluid of Alzheimer's and de novo Parkinson's disease patients. , 1995, Neuroscience letters.
[59] M. Ross,et al. N-acetyl-cysteine suppresses amniotic fluid and placenta inflammatory cytokine responses to lipopolysaccharide in rats. , 2006, American journal of obstetrics and gynecology.
[60] S. Takashima,et al. Endotoxin, cerebral blood flow, amino acids and brain damage in young rabbits , 1988, Brain and Development.
[61] D. Loeffler,et al. Effects of Enhanced Striatal Dopamine Turnover In Vivo on Glutathione Oxidation , 1994, Clinical neuropharmacology.
[62] Andre Parent,et al. Presence of reactive microglia in monkey substantia nigra years after 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine administration , 2003, Annals of neurology.
[63] J. Langston,et al. Evidence of active nerve cell degeneration in the substantia nigra of humans years after 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine exposure , 1999, Annals of neurology.
[64] H. Przuntek,et al. Interleukin-6 levels in cerebrospinal fluid inversely correlate to severity of Parkinson's disease. , 1998, Acta neurologica Scandinavica.
[65] G. Bing,et al. Up-regulation of inducible nitric oxide synthase in the substantia nigra by lipopolysaccharide causes microglial activation and neurodegeneration , 2003, Neurobiology of Disease.
[66] D. Perl,et al. Protein Nitration in Parkinson's Disease , 1998, Journal of neuropathology and experimental neurology.
[67] J. Xie,et al. Parkinson's Disease Brain Mitochondrial Complex I Has Oxidatively Damaged Subunits and Is Functionally Impaired and Misassembled , 2006, The Journal of Neuroscience.
[68] P. Riederer,et al. Brain β2-microglobulin levels are elevated in the striatum in Parkinson's diseaselevels are elevated in the striatum in Parkinson's disease , 1995 .
[69] W. Le,et al. Minocycline inhibits microglial activation and protects nigral cells after 6-hydroxydopamine injection into mouse striatum , 2001, Brain Research.
[70] M. Block,et al. Microglia and inflammation-mediated neurodegeneration: Multiple triggers with a common mechanism , 2005, Progress in Neurobiology.
[71] H. Przuntek,et al. Short communication Interleukin‐6 levels in cerebrospinal fluid inversely correlate to severity of Parkinson's disease , 1998, Acta neurologica Scandinavica.
[72] D. Reif,et al. Nitric oxide mediates iron release from ferritin. , 1990, Archives of biochemistry and biophysics.
[73] K. Mohanakumar,et al. Non-steroidal anti-inflammatory drug sodium salicylate, but not diclofenac or celecoxib, protects against 1-methyl-4-phenyl pyridinium-induced dopaminergic neurotoxicity in rats , 2003, Brain Research.
[74] T. J. Cunningham,et al. Differential immunochemical markers reveal the normal distribution of brain macrophages and microglia in the developing rat brain , 1991, The Journal of comparative neurology.
[75] E. Esposito,et al. Aspirin protects striatal dopaminergic neurons from neurotoxin-induced degeneration: An in vivo microdialysis study , 2006, Brain Research.
[76] D. Tse,et al. Potential oxidative pathways of brain catecholamines. , 1976, Journal of medicinal chemistry.
[77] L. Zon,et al. Requirement for ceramide-initiated SAPK/JNK signalling in stress-induced apoptosis , 1996, Nature.
[78] Andreas Hald,et al. Oxidative stress and inflammation in Parkinson's disease: is there a causal link? , 2005, Experimental Neurology.
[79] D. Miller,et al. Mice deficient in TNF receptors are protected against dopaminergic neurotoxicity: Implications for Parkinson's disease , 2002, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[80] K. Tanaka,et al. Increase in level of tumor necrosis factor (TNF)-alpha in 6-hydroxydopamine-lesioned striatum in rats without influence of systemic L-DOPA on the TNF-alpha induction. , 1999, Neuroscience letters.
[81] J. Dichgans,et al. Deficiency of Inducible Nitric Oxide Synthase Protects Against MPTP Toxicity In Vivo , 2000, Journal of neurochemistry.
[82] R. Flavell,et al. Apoptosis. Death of a monopoly? , 2001, Science.
[83] W. Le,et al. Antibodies from patients with Parkinson's disease react with protein modified by dopamine oxidation , 1998, Journal of neuroscience research.
[84] Pathogenic role of glial cells in Parkinson's disease , 2003, Movement disorders : official journal of the Movement Disorder Society.
[85] Peter Riederer,et al. Interleukin-1β and interleukin-6 are elevated in the cerebrospinal fluid of Alzheimer's and de novo Parkinson's disease patients , 1995, Neuroscience Letters.
[86] Barry Halliwell,et al. Oxidative stress and neurodegeneration: where are we now? , 2006, Journal of neurochemistry.
[87] H. Okano,et al. Caspase-mediated oligodendrocyte cell death in the pathogenesis of autoimmune demyelination , 2003, Neuroscience Research.
[88] J. Cano,et al. Lipopolysaccharide Intranigral Injection Induces Inflammatory Reaction and Damage in Nigrostriatal Dopaminergic System , 1998, Journal of neurochemistry.
[89] Robert M Friedlander,et al. Apoptosis and caspases in neurodegenerative diseases. , 2003, The New England journal of medicine.
[90] A. Leviton,et al. Does prepregnancy bacterial vaginosis increase a mother's risk of having a preterm infant with cerebral palsy? , 1997, Developmental medicine and child neurology.
[91] J S Beckman,et al. Peroxynitrite-mediated tyrosine nitration catalyzed by superoxide dismutase. , 1992, Archives of biochemistry and biophysics.
[92] R. Mohney,et al. Regional Difference in Susceptibility to Lipopolysaccharide-Induced Neurotoxicity in the Rat Brain: Role of Microglia , 2000, The Journal of Neuroscience.
[93] S. Daniel,et al. Glial pathology but absence of apoptotic nigral neurons in long‐standing Parkinson's disease , 1998, Movement disorders : official journal of the Movement Disorder Society.
[94] E. Joe,et al. Gangliosides activate microglia via protein kinase C and NADPH oxidase , 2004, Glia.
[95] N. Rothwell,et al. Cytokines and acute neurodegeneration , 1997, Molecular Psychiatry.
[96] S. Rivest,et al. Circulating cell wall components derived from gram‐negative, not gram‐positive, bacteria cause a profound induction of the gene‐encoding Toll‐like receptor 2 in the CNS , 2001, Journal of neurochemistry.
[97] N. Cooper,et al. The C5a complement activation peptide increases IL-1β and IL-6 release from amyloid-β primed human monocytes: implications for Alzheimer’s disease , 2000, Journal of Neuroimmunology.
[98] J. Cano,et al. Minocycline reduces the lipopolysaccharide-induced inflammatory reaction, peroxynitrite-mediated nitration of proteins, disruption of the blood–brain barrier, and damage in the nigral dopaminergic system , 2004, Neurobiology of Disease.
[99] Shuxian Hu,et al. Nitric oxide production and neurotoxicity mediated by activated microglia from human versus mouse brain. , 1994, The Journal of infectious diseases.
[100] H. Neumann. Control of glial immune function by neurons , 2001, Glia.
[101] P. Mcgeer,et al. Inflammation and neurodegeneration in Parkinson's disease. , 2004, Parkinsonism & related disorders.
[102] Todd B. Sherer,et al. Chronic systemic pesticide exposure reproduces features of Parkinson's disease , 2000, Nature Neuroscience.
[103] D. Bonifati,et al. Role of complement in neurodegeneration and neuroinflammation. , 2007, Molecular immunology.
[104] D. Clarke,et al. A Role for Tumor Necrosis Factor α in Death of Dopaminergic Neurons Following Neural Transplantation , 2002, Experimental Neurology.
[105] B. Babior. Phagocytes and oxidative stress. , 2000, The American journal of medicine.
[106] Y. Mizuno,et al. Inflammation and infection in Parkinson's disease. , 2006, Histology and histopathology.
[107] M. Shin,et al. Production of tumor necrosis factor and other cytokines by astrocytes stimulated with lipopolysaccharide or a neurotropic virus. , 1989, Proceedings of the National Academy of Sciences of the United States of America.
[108] H. Ichinose,et al. Caspase activities and tumor necrosis factor receptor R1 (p55) level are elevated in the substantia nigra from Parkinsonian brain , 2000, Journal of Neural Transmission.
[109] P. Mcgeer,et al. Lewy bodies in Parkinson's disease are recognized by antibodies to complement proteins , 2004, Acta Neuropathologica.
[110] W. Willett,et al. Nonsteroidal anti-inflammatory drugs and the risk of Parkinson disease. , 2003, Archives of neurology.
[111] P. Ruppel,et al. Competitive irreversible inhibition of dopamine uptake by 6-hydroxydopamine. , 1993, Research communications in chemical pathology and pharmacology.
[112] Timothy A. Springer,et al. Purified intercellular adhesion molecule-1 (ICAM-1) is a ligand for lymphocyte function-associated antigen 1 (LFA-1) , 1987, Cell.
[113] E. Hirsch,et al. The inflammatory response in the Parkinson brain , 2001, Clinical Neuroscience Research.
[114] K. Wakabayashi,et al. The cellular pathology of Parkinson's disease , 2001, Neuropathology (Kyoto. 1993).
[115] Y. Hannun,et al. Programmed cell death induced by ceramide. , 1993, Science.
[116] B. Jeune,et al. Few microorganisms associated with bacterial vaginosis may constitute the pathologic core: a population-based microbiologic study among 3596 pregnant women. , 1998, American journal of obstetrics and gynecology.
[117] P. Carvey,et al. Progressive dopamine neuron loss following supra-nigral lipopolysaccharide (LPS) infusion into rats exposed to LPS prenatally , 2006, Experimental Neurology.
[118] P. Carvey,et al. In utero bacterial endotoxin exposure causes loss of tyrosine hydroxylase neurons in the postnatal rat midbrain , 2002, Movement disorders : official journal of the Movement Disorder Society.
[119] P. Mcgeer,et al. Reactive microglia are positive for HLA‐DR in the substantia nigra of Parkinson's and Alzheimer's disease brains , 1988, Neurology.
[120] F. Aloisi. Immune function of microglia , 2001, Glia.
[121] S. Pennathur,et al. Mass Spectrometric Quantification of 3-Nitrotyrosine, ortho-Tyrosine, and o,o′-Dityrosine in Brain Tissue of 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated Mice, a Model of Oxidative Stress in Parkinson's Disease* , 1999, The Journal of Biological Chemistry.
[122] R. Flavell,et al. Death of a Monopoly? , 2001, Science.
[123] Wenjie Xie,et al. Microglial Activation and Dopaminergic Cell Injury: An In Vitro Model Relevant to Parkinson's Disease , 2001, The Journal of Neuroscience.
[124] O. Isacson,et al. Neuroinflammation of the nigrostriatal pathway during progressive 6‐OHDA dopamine degeneration in rats monitored by immunohistochemistry and PET imaging , 2002, The European journal of neuroscience.
[125] P. Jenner,et al. The acute and the long‐term effects of nigral lipopolysaccharide administration on dopaminergic dysfunction and glial cell activation , 2005, The European journal of neuroscience.
[126] P. Jenner. Parkinson's disease, pesticides and mitochondrial dysfunction , 2001, Trends in Neurosciences.
[127] R. Testi,et al. Sphingomyelin breakdown and cell fate. , 1996, Trends in biochemical sciences.
[128] S. Lee,et al. Tetrahydrobiopterin causes mitochondrial dysfunction in dopaminergic cells: Implications for Parkinson's disease , 2006, Neurochemistry International.
[129] Wei Zhang,et al. The role of microglia in paraquat-induced dopaminergic neurotoxicity. , 2005, Antioxidants & redox signaling.
[130] J. Cano,et al. The Single Intranigral Injection of LPS as a New Model for Studying the Selective Effects of Inflammatory Reactions on Dopaminergic System , 2000, Neurobiology of Disease.
[131] George Kollias,et al. Uncoupling the Proinflammatory from the Immunosuppressive Properties of Tumor Necrosis Factor (Tnf) at the P55 TNF Receptor Level , 2001, The Journal of experimental medicine.
[132] A. Schapira,et al. Evidence for mitochondrial dysfunction in Parkinson's disease—a critical appraisal , 2004, Movement disorders : official journal of the Movement Disorder Society.
[133] A. Członkowska,et al. The Inflammatory Reaction Following 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine Intoxication in Mouse , 1999, Experimental Neurology.
[134] M. Schwartz,et al. Increased post-traumatic survival of neurons in IL-6-knockout mice on a background of EAE susceptibility , 2001, Journal of Neuroimmunology.
[135] G. Kreutzberg. Microglia: a sensor for pathological events in the CNS , 1996, Trends in Neurosciences.
[136] Haruhiko Akiyama,et al. Rate of cell death in parkinsonism indicates active neuropathological process , 1988, Annals of neurology.
[137] S. Rivest,et al. Regulation of the Genes Encoding Interleukin‐6, Its Receptor, and gp130 in the Rat Brain in Response to the Immune Activator Lipopolysaccharide and the Proinflammatory Cytokine Interleukin‐1β , 1997, Journal of neurochemistry.
[138] Erzsebet Kokovay,et al. Bone marrow-derived microglia contribute to the neuroinflammatory response and express iNOS in the MPTP mouse model of Parkinson's disease , 2005, Neurobiology of Disease.
[139] H. Wekerle,et al. Neuronal Control of the Immune Response in the Central Nervous System: Linking Brain Immunity to Neurodegeneration , 1998, Journal of neuropathology and experimental neurology.
[140] T. Dawson,et al. Mechanisms of nitric oxide-mediated neurotoxicity in primary brain cultures , 1993, The Journal of neuroscience : the official journal of the Society for Neuroscience.
[141] Stephanie B. Conant,et al. Complement activation in the Parkinson's disease substantia nigra: an immunocytochemical study , 2006, Journal of Neuroinflammation.
[142] R. Rosenberg. Mitochondrial therapy for Parkinson disease. , 2002, Archives of neurology.
[143] T. Montine,et al. Parkinson's disease is associated with oxidative damage to cytoplasmic DNA and RNA in substantia nigra neurons. , 1999, The American journal of pathology.
[144] Joseph K. H. Ma,et al. THE DUAL EFFECT OF THE PARTICULATE AND ORGANIC COMPONENTS OF DIESEL EXHAUST PARTICLES ON THE ALTERATION OF PULMONARY IMMUNE/INFLAMMATORY RESPONSES AND METABOLIC ENZYMES , 2002, Journal of environmental science and health. Part C, Environmental carcinogenesis & ecotoxicology reviews.
[145] B. Engelhardt,et al. Intracellular Domain of Brain Endothelial Intercellular Adhesion Molecule-1 Is Essential for T Lymphocyte-Mediated Signaling and Migration1 , 2003, The Journal of Immunology.
[146] U. Gimsa,et al. Phagocytosis of neuronal or glial debris by microglial cells: Upregulation of MHC class II expression and multinuclear giant cell formation in vitro , 2000, Glia.
[147] M. Hoehn,et al. Parkinsonism , 1967, Neurology.
[148] G. Deuschl,et al. Activation of microglia by human neuromelanin is NF‐κB‐dependent and involves p38 mitogen‐activated protein kinase: implications for Parkinson's disease , 2003, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[149] H. Rus,et al. The complement system in central nervous system diseases , 2001, Immunologic research.
[150] S. Mandel,et al. Using cDNA microarray to assess Parkinson's disease models and the effects of neuroprotective drugs. , 2003, Trends in pharmacological sciences.
[151] Jos Prickaerts,et al. Modeling Parkinson's Disease in Rats: An Evaluation of 6-OHDA Lesions of the Nigrostriatal Pathway , 2002, Experimental Neurology.
[152] G. Halliday,et al. An inflammatory review of Parkinson’s disease , 2002, Progress in Neurobiology.
[153] J. Bonnefoy,et al. A new role for CD23 in inflammation. , 1996, Immunology today.
[154] K. Lim,et al. The Cast of Molecular Characters in Parkinson's Disease , 2003, Annals of the New York Academy of Sciences.
[155] Y. Glinka,et al. Dopamine Neurotoxicity: Inhibition of Mitochondrial Respiration , 1995, Journal of neurochemistry.
[156] E. Hirsch,et al. FcεRII/CD23 Is Expressed in Parkinson’s Disease and Induces, In Vitro, Production of Nitric Oxide and Tumor Necrosis Factor-α in Glial Cells , 1999, The Journal of Neuroscience.
[157] C. Carter,et al. Aspirin and Salicylate Protect Against MPTP‐Induced Dopamine Depletion in Mice , 1998, Journal of neurochemistry.
[158] A. Członkowska,et al. Microglial reaction in MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) induced Parkinson's disease mice model. , 1996, Neurodegeneration : a journal for neurodegenerative disorders, neuroprotection, and neuroregeneration.
[159] Ted M. Dawson,et al. Inducible nitric oxide synthase stimulates dopaminergic neurodegeneration in the MPTP model of Parkinson disease , 1999, Nature Medicine.
[160] P. Södersten,et al. Increased cerebrospinal fluid concentration of nitrite in Parkinson's disease , 1995, Neuroreport.
[161] I. Pérez-Otaño,et al. Glia-dependent neurotoxicity and neuroprotection in mesencephalic cultures , 1995, Brain Research.
[162] J. Cano,et al. The degenerative effect of a single intranigral injection of LPS on the dopaminergic system is prevented by dexamethasone, and not mimicked by rh‐TNF‐α, IL‐1β and IFN‐γ , 2002 .
[163] F. Fan,et al. Redox regulation of glial inflammatory response to lipopolysaccharide and interferonγ , 2004, Journal of neuroscience research.
[164] M. Vila,et al. NADPH oxidase mediates oxidative stress in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[165] M. Moskowitz,et al. Dual Role of Caspase-11 in Mediating Activation of Caspase-1 and Caspase-3 under Pathological Conditions , 2000, The Journal of cell biology.
[166] P. Riederer,et al. Oxidative stress: free radical production in neural degeneration. , 1994, Pharmacology & therapeutics.
[167] B. Liu,et al. Synergistic dopaminergic neurotoxicity of MPTP and inflammogen lipopolysaccharide: relevance to the etiology of Parkinson's disease , 2003, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[168] J. Cano,et al. Inflammatory process as a determinant factor for the degeneration of substantia nigra dopaminergic neurons , 2004, Journal of Neural Transmission.
[169] P. Carvey,et al. 6‐Hydroxydopamine‐induced alterations in blood–brain barrier permeability , 2005, The European journal of neuroscience.
[170] Dong-Kug Choi,et al. Blockade of Microglial Activation Is Neuroprotective in the 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine Mouse Model of Parkinson Disease , 2002, The Journal of Neuroscience.
[171] S. Mohand-Said,et al. Neurodegenerative and Neuroprotective Effects of Tumor Necrosis Factor (TNF) in Retinal Ischemia: Opposite Roles of TNF Receptor 1 and TNF Receptor 2 , 2002, The Journal of Neuroscience.
[172] Y. Agid,et al. Nitric oxide synthase and neuronal vulnerability in parkinson's disease , 1996, Neuroscience.
[173] J. O'Callaghan,et al. Minocycline attenuates microglial activation but fails to mitigate striatal dopaminergic neurotoxicity: role of tumor necrosis factor‐α , 2006, Journal of neurochemistry.
[174] G. Cohen,et al. Coupling of Dopamine Oxidation (Monoamine Oxidase Activity) to Glutathione Oxidation Via the Generation of Hydrogen Peroxide in Rat Brain Homogenates , 1981, Journal of neurochemistry.
[175] J. Obeso,et al. Dopamine Cell Degeneration Induced by Intraventricular Administration of 6-Hydroxydopamine in the Rat: Similarities with Cell Loss in Parkinson's Disease , 2001, Experimental Neurology.
[176] P. Mcgeer,et al. Inflammation in Parkinson's disease. , 2001, Advances in neurology.
[177] S. Rivest,et al. Bone marrow stem cells have the ability to populate the entire central nervous system into fully differentiated parenchymal microglia , 2004, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[178] P. Damier,et al. Glial cells and inflammation in parkinson's disease: A role in neurodegeneration? , 1998, Annals of neurology.
[179] C. Tanner. Is the cause of Parkinson's disease environmental or hereditary? Evidence from twin studies. , 2003, Advances in neurology.